Autologous bone marrow transplantation for Hodgkin's disease--a five-year single centre experience.
The results from 40 patients who have undergone autologous bone marrow transplantation (ABMT) for relapsed or refractory Hodgkin's disease between March 1988 and September 1992 have been analysed. In contrast to our results in patients with relapsed HD, our results in patients with refractory HD are comparatively poor. Conventional salvage chemotherapy also seems inappropriate in these patients and we therefore believe they should be offered high-dose chemotherapy before their disease becomes refractory to conventionally scheduled regimens. Peripheral blood stem cell (PBSC) transplant now offers an attractive alternative to ABMT and may replace both intensive salvage chemotherapy and ABMT as the optimum treatment for patients who fail to respond to conventional chemotherapy regimens.
Ager
S
S
Department of Haematology, Addenbrooke's Hospital, Cambridge, UK.
Wimperis
J Z
JZ
Tolliday
B
B
Jestice
K
K
Bass
G
G
Baglin
T
T
Marcus
R E
RE
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000401:mortality / Q000706:statistics & numerical data*; D003131:Combined Modality Therapy; D004351:Drug Resistance; D005260:Female; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D015993:Life Tables; D008297:Male; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D016879:Salvage Therapy; D016019:Survival Analysis; D016896:Treatment Outcome